Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

WuXi PharmaTech and DNAnexus Form Genomic Cloud Partnership; WuXi Invests $15 Million

publication date: Apr 22, 2015
WuXi PharmaTech, the China-US CRO/CMO, deepened its commitment to genomics by making a $15 million investment in DNAnexus, a California company with a cloud-based genomic informatics and data management platform. WuXi and DNAnexus will partner to allow web-based access to the genomic services of another WuXi subsidiary, WuXi NextCode Genomics, providing NextCode's proprietary database infrastructure along with its clinical and research tools on the DNAnexus cloud. The partnership helps WuXi accomplish one of its major goals: to create an open access platform that offers all of its CRO services to researchers anywhere in the world. More details....

Stock Symbol: (NYSE: WX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital